NCT01651000View on ClinicalTrials.gov

Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency

PHASE3CompletedINTERVENTIONAL

Enrollment

213

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions

Chronic Kidney DiseaseHyperparathyroidism, SecondaryVitamin D Deficiency

Interventions

DRUG

CTAP101 30 μg capsules

CTAP101 30 μg capsule taken daily at bedtime.

OTHER

Sugar pill to CTAP101 30 μg capsules

Sugar pill capsule (placebo to CTAP101 30 μg capsule) taken daily at bedtime.

Trial Locations (1)

60015

OPKO Renal, Bannockburn

All Listed Sponsors

lead

OPKO IP Holdings II, Inc.

INDUSTRY

NCT01651000 - Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency | Biotech Hunter | Biotech Hunter